Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Empirico Inc. is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 4 distinct examiners, which indicates some overlap in examiner assignments but still maintains a variety of perspectives. This variety requires the company to be prepared for different examination styles across its pending portfolio. Each examiner may focus on different aspects of the pharmaceutical claims.
The 5 pending office actions are concentrated within 2 distinct art units, suggesting that the technical scope of the applications is relatively focused. VANHORN, ABIGAIL LOUISE is the busiest examiner, holding 2 pending office actions. This concentration with a single examiner means that some of the pending actions are being reviewed by the same person, which can lead to more consistent outcomes for those specific cases. The remaining actions are handled by the other distinct examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 2 | 46.8% | +22.4% |
| ARIETI, RUTH SOPHIA | 1 | 46.7% | +71.1% |
| YU, DAVID TUYANG | 1 | 100.0% | +0.0% |
| WHITEMAN, BRIAN A | 1 | 68.5% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037959 | TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS | YU, DAVID TUYANG | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569113 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | VANHORN, ABIGAIL LOUISE | — |
| 18567011 | TREATMENT OF ANGPTL4 RELATED DISEASES | ARIETI, RUTH SOPHIA | — |
| 18037960 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028992 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | WHITEMAN, BRIAN A | 30d |
| 18569113 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | VANHORN, ABIGAIL LOUISE | — |
| 18567011 | TREATMENT OF ANGPTL4 RELATED DISEASES | ARIETI, RUTH SOPHIA | — |
| 18037960 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | VANHORN, ABIGAIL LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1636 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569113 | TREATMENT OF DKK2 RELATED DISEASES AND DISORDERS | VANHORN, ABIGAIL LOUISE | — | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18567011 | TREATMENT OF ANGPTL4 RELATED DISEASES | ARIETI, RUTH SOPHIA | 1635 | §102§103§112Other | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18037960 | GALNAC COMPOSITIONS FOR IMPROVING SIRNA BIOAVAILABILITY | VANHORN, ABIGAIL LOUISE | 1636 | §103§112 | Non-Final OA | — | Pending | May 19, 2023 |
| 18037959 | TREATMENT OF SOS2 RELATED DISEASES AND DISORDERS | YU, DAVID TUYANG | 1635 | §102§103§112DP | Non-Final OA | — | Pending | May 19, 2023 |
| 18028992 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES | WHITEMAN, BRIAN A | 1636 | DP | Final Rejection | 30d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial